"The Anglo-Swedish drugmaker (AstraZeneca) said on Tuesday that it had struck a deal for Seattle-based Icosavax, which has a potential vaccine for two common respiratory diseases that can cause severe illness in older adults: respiratory syncytial virus (RSV) and human metapneumovirus." 

https://www.ft.com/content/1ededcba-dd40-455e-8fe0-fc3084389184